Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
Tirzepatide is a 39-amino-acid synthetic peptide engineered to activate two incretin receptors at once: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It is the first approved drug in this dual-agonist class. Like semaglutide, it carries a fatty acid side chain that binds to albumin, extending the half-life to roughly five days and enabling once-weekly dosing.
It is the same molecule under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Both are subcutaneous-only.
History and approval timeline
Eli Lilly published the discovery of LY3298176 (the experimental designation) in 2018, describing it as a "twincretin" optimized for the GIP receptor with partial agonism at GLP-1. The development program ran through the SURPASS trials (diabetes) and SURMOUNT trials (obesity).
- May 2022 — FDA approves Mounjaro for adults with type 2 diabetes.
- November 2023 — FDA approves Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
- December 2024 — FDA approves Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first medication approved for this indication.
- 2025 — Tirzepatide demonstrates superiority over semaglutide for weight loss in the head-to-head SURMOUNT-5 trial.
In the pivotal SURMOUNT-1 trial, the highest tirzepatide dose (15 mg weekly) produced a mean weight loss of about 21% from baseline over 72 weeks — the largest effect ever recorded for an approved weight-loss medication.
Mechanism
The dual mechanism distinguishes tirzepatide from semaglutide:
- GLP-1 receptor activation drives the same effects described for semaglutide: glucose-dependent insulin release, glucagon suppression, slowed gastric emptying, and central appetite regulation.
- GIP receptor activation is thought to add complementary effects — improved insulin sensitivity in adipose tissue, reduced food intake through additional central pathways, and possibly an attenuation of the nausea associated with pure GLP-1 agonism.
Tirzepatide binds GIP receptors with affinity similar to native GIP but binds GLP-1 receptors with five-fold lower affinity than native GLP-1 — a deliberate design choice to balance the two pathways.
Half-life and dosing cadence
Published terminal half-life is approximately 5 days. Once-weekly subcutaneous injection produces stable plasma concentrations; steady state is reached after roughly 4 weeks.
The FDA labels for both brands specify monthly dose escalation to manage gastrointestinal side effects:
- Mounjaro (T2D): Start at 2.5 mg weekly for 4 weeks → 5 mg → may escalate every 4 weeks through 7.5, 10, 12.5, and 15 mg → maintenance from 5 to 15 mg weekly.
- Zepbound (weight management and OSA): Same escalation schedule. Maintenance doses tested in trials: 5, 10, and 15 mg weekly.
Like semaglutide, the 2.5 mg starting dose is a tolerability dose, not a therapeutic dose. Escalation should not be advanced more frequently than every 4 weeks per the label.
Reconstitution example (for compounded vials)
Branded tirzepatide ships in pre-filled pens with fixed doses. Compounded tirzepatide is often supplied lyophilized in 5 mg, 10 mg, 15 mg, 30 mg, or 60 mg vials.
A 30 mg vial reconstituted with 2 mL of bacteriostatic water yields 15 mg/mL. On a 1 mL U-100 insulin syringe, 17 units (0.17 mL) contains 2.5 mg — the typical starting dose. Vial's calculator handles the conversion automatically.
What to know
- Common side effects in SURPASS and SURMOUNT trials: nausea, diarrhea, vomiting, constipation, decreased appetite. Most mild-to-moderate and concentrated during escalation.
- Boxed warning. FDA labels carry a boxed warning regarding risk of thyroid C-cell tumors based on rodent studies; contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
- Pancreatitis. Reported in post-marketing data; discontinue if suspected.
- Hypoglycemia. Low risk as monotherapy; meaningful risk when combined with insulin or sulfonylureas.
- Storage. Pre-filled pens: refrigerate before use, may be kept at room temperature for up to 21 days. Compounded lyophilized: refrigerate after reconstitution and use within the stability window provided by the compounder.
- Compounded versions. As of October 2024 the FDA declared the tirzepatide shortage resolved and has actively restricted compounded versions; legal access to compounded tirzepatide is now severely limited.
Sources
- 1.Frias JP et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM.
- 2.Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM.
- 3.FDA Prescribing Information — Zepbound (tirzepatide) injection.
- 4.FDA Prescribing Information — Mounjaro (tirzepatide) injection.
- 5.Coskun T et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Molecular Metabolism.